Intestinal Dysbiosis, the Tryptophan Pathway and Nonalcoholic Steatohepatitis

International Journal of Tryptophan Research

article

Jiezhong Chen¹  Luis Vitetta¹  Jeremy D Henson¹  Sean Hall¹ 

[1] Research Department, Medlab Clinical;Faculty of Medicine and Health, The University of Sydney;Faculty of Medicine, Prince of Wales Clinical School, The University of New South Wales

关键词: Nonalcoholic steatohepatitis;    intestinal microbiome;    dysbiosis;    inflammation;    tryptophan;   

DOI  :  10.1177/11786469211070533

学科分类：生理学与病理学

来源: Sage Journals

【 摘 要 】

Non-alcoholic fatty liver disease (NAFLD) progresses from simple steatosis to steatohepatitis (NASH), which may then progress to the development of cirrhosis and hepatocarcinoma. NASH is characterized by both steatosis and inflammation. Control of inflammation in NASH is a key step for the prevention of disease progression to severe sequalae. Intestinal dysbiosis has been recognized to be an important causal factor in the pathogenesis of NASH, involving both the accumulation of lipids and aggravation of inflammation. The effects of gut dysbiosis are mediated by adverse shifts of various intestinal commensal bacterial genera and their associated metabolites such as butyrate, tryptophan, and bile acids. In this review, we focus on the roles of tryptophan and its metabolites in NASH in association with intestinal dysbiosis and discuss possible therapeutic implications.

【 授权许可】

CC BY|CC BY-NC